Pediatric Growth Hormone Deficiency Market Is Expected To Grow During the Study Period (2019-2032), DelveInsight

DelveInsight's Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Pediatric Growth Hormone Deficiency Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Pediatric Growth Hormone Deficiency Overview

Pediatric Growth Hormone Deficiency (PGHD) occurs when the pituitary gland does not make enough growth hormone. It can be caused by damage to the pituitary gland or another gland called the hypothalamus. The injury can occur before birth (congenital), or during or after birth (acquired). The child is more at risk for GH deficiency if they have any of these like brain injury, brain tumor, and radiation treatment to the head. To diagnose the GH deficiency, the healthcare providers need to check for conditions such as normal variations of growth, such as familial short stature; other disorders, such as thyroid hormone deficiency or kidney disease, and genetic conditions. The tests like blood tests, X-rays, CT scans, and MRI. Treatment is mainly done with daily injections of synthetic growth hormone, results are often seen as soon as 3-4 months after treatment starts. The treatment can last several years until late puberty when growing is finished.

Download a Free Sample Report of Pediatric Growth Hormone Deficiency Market Research, Size, Share, and Forecast @ https://www.delveinsight.com/sample-request/pediatric-growth-hormone-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key highlights of the Pediatric Growth Hormone Deficiency Market Report
• As per the study by Bonfig Walter et al. the Growth Hormone Deficiency prevalence ranges between 1:3500 and 1:8700 in Germany.
• According to Boston's Children's Hospital, about one in 4,000 to 10,000 children have a growth hormone deficiency.
• According to Brod Meryl et al., the prevalence of childhood Growth Hormone Deficiency reported in published studies is within the range of 1.8-2.9 per 10,000 in Europe.
• According to the NORD, Growth hormone deficiency affects males and females equally. However, given the greater concern for boys with short stature in most societies, diagnosis tends to favor males over females. About 73% of patients with idiopathic GHD in the NCGS were male. Additionally, patients with GHD from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% male.

Pediatric Growth Hormone Deficiency Market Size

Pediatric Growth Hormone Deficiency Market Size is anticipated to increase in the coming years owing to the increasing prevalent population and expected entry of long-acting hGH emerging therapies for PGHD treatment in the 7MM. Of the emerging therapies, the most anticipated product to get launched in the market includes TransCon hGH, Somapacitan, Somatrogon, LUM-201, and others. These therapies are expected to change the Growth Hormone Deficiency market dynamics in the upcoming years. Some of the Growth Hormone Deficiency therapies also got Orphan designation.

The Pediatric Growth Hormone Deficiency market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Pediatric Growth Hormone Deficiency market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies. The report gives a thorough detail of the Pediatric Growth Hormone Deficiency market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Pediatric Growth Hormone Deficiency Epidemiology

The epidemiology section covers insights into the historical and current Pediatric Growth Hormone Deficiency patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Pediatric Growth Hormone Deficiency Epidemiology Segmentation
• Total Pediatric Growth Hormone Deficiency Prevalent Pool
• Total Pediatric Growth Hormone Deficiency Prevalent Patient Pool
• Pediatric Growth Hormone Deficiency Diagnosed Patient Pool
• Pediatric Growth Hormone Deficiency Treated Patient Pool

Explore more information about Pediatric Growth Hormone Deficiency prevalent cases, and epidemiology segmentation @ https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pediatric Growth Hormone Deficiency Market Therapeutics Analysis

The available therapeutic treatment options in the Pediatric Growth Hormone Deficiency (PGHD) landscape aims for long-term efficacy. As per DelveInsight, Pediatric Growth Hormone Deficiency (PGHD) market dynamics is anticipated to change in the coming years owing to the improvement in healthcare spending across the world.

Pediatric Growth Hormone Deficiency Market Companies include:
• Pfizer
• Opko health
• Novo Nordisk
• Ascendis Pharma
• Lumos Pharma, and Several Others

Pediatric Growth Hormone Deficiency Drugs include:
• LUM-201
• TransCon hGH
• Somapacitan
• Somatrogon, and Several Others

The pipeline for Pediatric Growth Hormone Deficiency (PGHD) is full of long-acting hGH as it is the major unmet need of this indication. On the other hand, the current pipeline is robust with late-stage products and will change the dynamics of the upcoming market.

Get More Detailed Insights Into the Pediatric Growth Hormone Deficiency Emerging Therapies & Key Pediatric Growth Hormone Deficiency Companies @ https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis
4. Pediatric Growth Hormone Deficiency Market Overview at a Glance
5. Pediatric Growth Hormone Deficiency Disease Background and Overview
6. Patient Journey
7. Pediatric Growth Hormone Deficiency Epidemiology and Patient Population
8. Pediatric Growth Hormone Deficiency Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Pediatric Growth Hormone Deficiency (PGHD) Treatment
11. Pediatric Growth Hormone Deficiency Marketed Products
12. Pediatric Growth Hormone Deficiency Emerging Therapies
13. Seven Major Pediatric Growth Hormone Deficiency Market Analysis
14. Attribute analysis
15. 7MM: Pediatric Growth Hormone Deficiency Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Pediatric Growth Hormone Deficiency Market Drivers
19. Pediatric Growth Hormone Deficiency Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Find out the Pediatric Growth Hormone Deficiency Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/pediatric-growth-hormone-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science verticals and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.